375,000 Shares in Dyne Therapeutics, Inc. (NASDAQ:DYN) Acquired by Federated Hermes Inc.

Federated Hermes Inc. bought a new position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 375,000 shares of the company's stock, valued at approximately $4,988,000. Federated Hermes Inc. owned about 0.61% of Dyne Therapeutics as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the company. Braidwell LP raised its stake in Dyne Therapeutics by 32.2% during the third quarter. Braidwell LP now owns 1,821,972 shares of the company's stock worth $16,325,000 after buying an additional 444,100 shares during the last quarter. Armistice Capital LLC raised its stake in Dyne Therapeutics by 31.6% during the third quarter. Armistice Capital LLC now owns 1,200,000 shares of the company's stock worth $10,752,000 after buying an additional 288,000 shares during the last quarter. Vivo Capital LLC raised its stake in Dyne Therapeutics by 79.2% during the third quarter. Vivo Capital LLC now owns 1,035,136 shares of the company's stock worth $9,275,000 after buying an additional 457,494 shares during the last quarter. Assenagon Asset Management S.A. increased its stake in Dyne Therapeutics by 24.5% in the third quarter. Assenagon Asset Management S.A. now owns 721,474 shares of the company's stock valued at $6,464,000 after purchasing an additional 142,083 shares in the last quarter. Finally, Walleye Capital LLC bought a new stake in Dyne Therapeutics in the third quarter valued at $2,511,000. Institutional investors own 96.68% of the company's stock.

Analyst Upgrades and Downgrades

DYN has been the subject of several research analyst reports. Piper Sandler lifted their price target on shares of Dyne Therapeutics from $27.00 to $29.00 and gave the company an "overweight" rating in a research note on Wednesday, March 6th. HC Wainwright reaffirmed a "buy" rating and issued a $36.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, March 6th. Raymond James lifted their price target on shares of Dyne Therapeutics from $27.00 to $56.00 and gave the company a "strong-buy" rating in a research note on Thursday, January 4th. Oppenheimer reaffirmed an "outperform" rating and issued a $47.00 price target on shares of Dyne Therapeutics in a research note on Tuesday, March 26th. Finally, Chardan Capital boosted their target price on shares of Dyne Therapeutics from $20.00 to $31.00 and gave the stock a "buy" rating in a research report on Friday, March 8th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $37.43.

Insider Buying and Selling

In other news, SVP Richard William Scalzo sold 3,429 shares of the firm's stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total transaction of $94,297.50. Following the sale, the senior vice president now owns 124,228 shares in the company, valued at approximately $3,416,270. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, SVP Richard William Scalzo sold 3,429 shares of Dyne Therapeutics stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $27.50, for a total value of $94,297.50. Following the transaction, the senior vice president now owns 124,228 shares in the company, valued at approximately $3,416,270. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Venture Fund Xi L.P. Atlas sold 184,501 shares of Dyne Therapeutics stock in a transaction on Wednesday, February 21st. The stock was sold at an average price of $22.57, for a total transaction of $4,164,187.57. Following the completion of the transaction, the insider now owns 6,631,464 shares in the company, valued at approximately $149,672,142.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,875,432 shares of company stock valued at $44,368,530. Company insiders own 20.77% of the company's stock.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN traded up $1.04 during midday trading on Friday, hitting $24.73. 616,906 shares of the company's stock were exchanged, compared to its average volume of 1,946,024. The stock has a 50 day moving average price of $26.07 and a 200-day moving average price of $17.70. The company has a market cap of $2.13 billion, a PE ratio of -6.28 and a beta of 0.95. Dyne Therapeutics, Inc. has a 12 month low of $6.40 and a 12 month high of $30.27.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.17). On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.